FDA's ODAC delivers one loss, one win for AstraZeneca
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The FDA's Oncologic Drugs Advisory Committee (ODAC) has made decisions regarding AstraZeneca, resulting in both a loss and a win for the company. The nature of these decisions is not specified, but they appear to have had mixed outcomes for AstraZeneca. The specifics of the loss and the win are not detailed in the available information.